Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss
NCT02990403Phase 4Unknown
- Sponsor
- Shanghai First Maternal and Infant Health Hospital
- Start
- Oct 2014
- Primary completion
- Jun 2017
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aspirin, heparin, prednisone and polyvalent human immunoglobulin in recurrent pregnancy loss (RPL) (5 arms), sponsored by Shanghai First Maternal and Infant Health Hospital. Primary endpoint: Live birth. Status: unknown.
02
Drugs
aspirinheparinprednisonepolyvalent human immunoglobulin
03
Conditions
recurrent pregnancy loss (RPL)
Beyond the preview
Go deeper on NCT02990403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02990403.